Yorkshire Post - Business - - FRONT PAGE -

Avacta’s drug de­vel­op­ment divi­sion will hit the big time once Avacta has signed a li­cence deal with a big phar­ma­ceu­ti­cal firm.

This could be worth be­tween £14m to £28m in an up­front pay­ment, fol­lowed by other pay­ments as the drugs roll out.

Avacta hopes to get a li­cence deal in the next cou­ple of years.

The other side of the busi­ness is the use of Af­fimers in di­ag­nos­tics and this should make a profit in three years’ time.

Dr Smith said: “We cur­rently have a £20m mar­ket cap. We could see an im­prove­ment to our mar­ket cap of be­tween ten and twenty-fold.”

Newspapers in English

Newspapers from UK

© PressReader. All rights reserved.